Academic Journal
Q1JACC: Heart Failure
About JACC: Heart Failure
JACC: Heart Failure is a scholarly journal published by Elsevier Inc.. SCImago 2025 places it in Q1 with an SJR of 4.036 and an H-index of 126.
Its listed coverage is 2013-2026 and its research categories include Cardiology and Cardiovascular Medicine (Q1). The 2025 dataset reports 369 documents and 3790 citations across the latest three-year reporting window.
JACC: Heart Failure – Advancing Research and Innovation in Heart Failure Care
JACC: Heart Failure is a premier peer-reviewed medical journal dedicated exclusively to the study and management of heart failure. Published by the American College of Cardiology (ACC), the journal serves as a vital resource for clinicians, researchers, and healthcare professionals focused on improving the lives of patients suffering from heart failure, one of the leading causes of hospitalization and mortality worldwide.
What is JACC: Heart Failure?
Launched as part of the Journal of the American College of Cardiology (JACC) family, JACC: Heart Failure delivers cutting-edge research, clinical insights, and evidence-based practices related to all aspects of heart failure. From novel therapeutic strategies to diagnostic tools and patient-centered care models, the journal covers a wide range of topics that reflect the evolving landscape of cardiology.
With a strong emphasis on both clinical and translational research, JACC: Heart Failure publishes original investigations, comprehensive reviews, editorials, and case reports that help bridge the gap between scientific discovery and clinical application. The journal’s content is rigorously peer-reviewed and curated by leading experts in the field.
Why JACC: Heart Failure Matters
Heart failure is a complex syndrome that affects millions globally and poses significant challenges to patients and healthcare systems alike. As new therapies and technologies emerge, clinicians need access to reliable, up-to-date information to guide treatment decisions and improve patient outcomes. JACC: Heart Failure addresses this need by providing high-quality, evidence-based content that reflects the latest scientific advancements.
The journal’s impact factor and growing readership make it a trusted source within the cardiovascular community. It plays a key role in shaping clinical guidelines and informing policy decisions related to heart failure care.
Topics Covered by JACC: Heart Failure
JACC: Heart Failure features research and clinical studies on a wide array of heart failure-related topics, including:
-
Acute and chronic heart failure management
-
Advanced heart failure therapies, including mechanical circulatory support and transplantation
-
Pharmacological and device-based treatments
-
Biomarkers and imaging techniques
-
Patient quality of life and outcomes
-
Health disparities and global perspectives on heart failure
-
Preventive strategies and risk reduction
-
Precision medicine and personalized care approaches
This wide-ranging scope ensures that the journal remains at the forefront of cardiology research and is highly relevant to healthcare professionals worldwide.
Accessing JACC: Heart Failure
JACC: Heart Failure is available both online and in print. Subscribers can access full-text articles through the JACC.org platform, which also offers search tools, article collections, and multimedia content like podcasts and expert interviews. Many articles are open access, ensuring that critical information is readily available to the broader medical community.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scope of JACC: Heart Failure – Advancing Research in Cardiovascular Care
JACC: Heart Failure is a premier peer-reviewed journal under the umbrella of the Journal of the American College of Cardiology (JACC). As a dedicated platform for the latest developments in heart failure, the journal serves as a critical resource for clinicians, researchers, and healthcare professionals worldwide. Its scope encompasses all aspects of heart failure, from pathophysiology and diagnosis to innovative therapies and clinical outcomes.
Focused on Comprehensive Heart Failure Research
The primary scope of JACC: Heart Failure includes high-quality original research that advances the understanding and treatment of heart failure. The journal covers a broad range of topics, such as:
-
Epidemiology and Risk Stratification
Studies analyzing the prevalence, incidence, and risk factors associated with heart failure, aiming to enhance early detection and prevention. -
Basic and Translational Science
Groundbreaking research that uncovers the molecular and cellular mechanisms of heart failure, facilitating the development of targeted therapies. -
Clinical Trials and Therapeutic Strategies
Reports on randomized clinical trials, observational studies, and real-world data that evaluate pharmacologic and device-based interventions. -
Advanced Heart Failure and Transplantation
Research addressing mechanical circulatory support, heart transplantation, and end-of-life care in patients with advanced heart failure. -
Imaging and Diagnostics
Innovations in cardiac imaging, biomarkers, and diagnostic tools that support early and accurate diagnosis.
Promoting Global Impact and Clinical Relevance
JACC: Heart Failure emphasizes clinical applicability and global relevance. The journal encourages submissions that address disparities in care, global health trends, and emerging challenges in the management of heart failure across diverse populations.
It also highlights state-of-the-art reviews, editorials, and clinical perspectives that synthesize current knowledge and guide best practices in heart failure care.
Interdisciplinary and Collaborative
The scope of the journal fosters collaboration across disciplines, bridging the gap between cardiology, internal medicine, surgery, pharmacology, and public health. With a commitment to publishing timely and impactful research, JACC: Heart Failure supports innovation and evidence-based care models to improve patient outcomes.
Why Publish in JACC: Heart Failure?
-
High Visibility and Impact Factor
The journal boasts a high impact factor, ensuring that research published within it reaches a wide audience and garners significant citations. -
Rigorous Peer Review
Each submission undergoes a meticulous review process by leading experts in the field, ensuring scientific integrity and clinical relevance. -
Global Readership
As part of the JACC family, the journal reaches cardiologists, healthcare providers, and researchers across the globe.
Recent Research Articles
Latest publications matched automatically by ISSN.
Stroke and Bleeding Risk in Cardiac Amyloidosis
Navid Noory, Jeppe K. Petersen, Oscar Westin, Eva Havers-Borgersen et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103147Efficacy and Safety of Simultaneous Initiation of SGLT2 Inhibitors and Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease or Heart Failure
Emily K. Yeung, Lauren Heath, Patrick B. Mark, Muthiah Vaduganathan et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103106Humanistic Machines
Sarah Hudson, Allison Strochlic, Joseph Maniaci, Jennifer A. Cowger et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103181Defining Clinically Meaningful Within-Patient Changes in Heart Failure
Amin Yehya, Rebecca Hahn, Barry Borlaug, Victoria Delgado et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103310Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes
Kershaw V. Patel, Leonard Chiu, Katelyn R. Garcia, L. Maria Belalcazar et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103296From Atherosclerosis to Heart Failure
Jelani K. Grant, Michelle D. Kelsey
2026-09 · DOI: 10.1016/j.jchf.2026.103315Endomyocardial Biopsy-Based Inflammatory Phenotypes Predict Outcomes in Virus-Negative Dilated and Inflammatory Cardiomyopathy
Christian Baumeier, Felicitas Escher, Ganna Aleshcheva, Gordon Wiegleb et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103185Beyond Aldosterone
Clara Saldarriaga, Bertram Pitt
2026-09 · DOI: 10.1016/j.jchf.2026.103157Real-World Analysis of Malnutrition and 1-Year Mortality in Patients Treated With Temporary Mechanical Circulatory Support
Michele Marchetta, Michele Golino, Joe Krenitsky, Abby Michaels et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103107Reappraising Left Ventricular Wall Thickness in Developing Clinical Suspicion for Transthyretin Cardiac Amyloidosis
Harsh Patolia, Michel Chedid El Helou, Alexandra Manaila, Faysal Massad et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103158Frailty Patterns, Reversibility, and Outcomes With a Magnetically Levitated Left Ventricular Assist Device
Nelson Wang, Ameesh Isath, Ivan Netuka, Ulrich Jorde et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103313Physician-Directed Patient Self-Management Using an Implantable IVC Congestion Sensor
Nir Uriel, Mandeep R. Mehra, Barry R. Greene, Kunjan Bhatt et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103011Psychiatric Disorders and Mortality in Heart Failure
Xingbo Mo, Hua Chen, Imre Janszky, Ulf Dahlström et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103098Insurance Type Is Associated With Management and Outcomes in Young Adults Hospitalized With Heart Failure
Wacim Benyoucef, Vi-Anh Hoang, R.J. Waken, Karen E. Joynt Maddox et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103108Full issue PDF
2026-09 · DOI: 10.1016/s2213-1779(26)00424-5Effect of Omecamtiv Mecarbil According to PREDICT-HF Risk Score
Misato Chimura, Kirsty McDowell, Pardeep S. Jhund, Kieran F. Docherty et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103302Patient-Facing Alerts in Heart Failure
Kannu Bansal, F. Perry Wilson
2026-09 · DOI: 10.1016/j.jchf.2026.103294Impact of “Door-to-Lactate Clearance” on Clinical Outcomes in Cardiogenic Shock
Chirag Mehta, Phinnara Has, Heena Asnani, Carl Atallah et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103104How Soon Is Now?
Evan P. Kransdorf, Trinh Do
2026-09 · DOI: 10.1016/j.jchf.2026.103186NOTIFY-HF
Joseph Assad, Nancy E. Briggs, Sidney Lo, Rohan Rajaratnam et al.
2026-09 · DOI: 10.1016/j.jchf.2026.103184Reviews
Community Reviews
Version History
April 20, 2025 at 9:07 am
April 20, 2025